Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
Status:
Terminated
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The aim of our study was to demonstrate that, during a percutaneous coronary intervention,
even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid
thrombus resolution and clinical improvement without concomitant differences in hemorrhagic
complications